Myasthenia gravis medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
==== Symptomatic treatments ==== | ==== Symptomatic treatments ==== | ||
An oral [[anticholinesterase]] like [[pyridostigmine]] is usually the first drug in [[Myasthenia gravis|MG]] patients.(5) these drugs can reduce the degradation of [[Acetylcholine|Ach]] in the [[synaptic cleft]].(7) [[Limb (anatomy)|limbs]] and [[bulbar]] muscles respond very well to these drugs but [[ocular]] [[symptoms]] including [[diplopia]] are resistance to these medications.(8) | |||
==== Chronic immunomodulating treatments ==== | ==== Chronic immunomodulating treatments ==== | ||
Revision as of 13:14, 21 June 2018
|
Myasthenia gravis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myasthenia gravis medical therapy On the Web |
|
American Roentgen Ray Society Images of Myasthenia gravis medical therapy |
|
Risk calculators and risk factors for Myasthenia gravis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
The mainstays of medical therapy for myasthenia gravis are:
Symptomatic treatments
An oral anticholinesterase like pyridostigmine is usually the first drug in MG patients.(5) these drugs can reduce the degradation of Ach in the synaptic cleft.(7) limbs and bulbar muscles respond very well to these drugs but ocular symptoms including diplopia are resistance to these medications.(8)
Chronic immunomodulating treatments
- glucocorticoids
- immunosuppressive drugs
- Azathioprine
- Mycophenolate
- Cyclosporine
- Tacrolimus
- Rituximab
- Methotrexate
- Etanercept
- Cyclophosphamide
Rapid immunomodulating treatments
- plasmapheresis
- intravenous immune globulin